Irritable Bowel Syndrome Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

Description

Persistence Market Research has recently released a comprehensive report on the worldwide market for Irritable Bowel Syndrome (IBS) treatments. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global IBS treatment market from 2024 to 2033.

Key Insights:

IBS Treatment Market Size (2024E): USD 3.9 Billion
Projected Market Value (2033F): USD 8.1 Billion
Global Market Growth Rate (CAGR 2024 to 2033): 8.4%

IBS Treatment Market - Report Scope:

Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. The treatment market for IBS includes a range of pharmaceuticals, dietary supplements, and lifestyle modification programs aimed at managing symptoms and improving patient quality of life. The market caters to hospitals, clinics, and homecare settings, offering a variety of treatment options, including antispasmodics, laxatives, fiber supplements, and probiotics.

Market growth is driven by the increasing prevalence of IBS, rising healthcare expenditures, and advancements in therapeutic options enhancing treatment efficacy and patient comfort.

Market Growth Drivers:

The global IBS treatment market is propelled by several key factors, including growing awareness about IBS and its impact on quality of life. The rising prevalence of IBS, particularly in developed countries, drives demand for effective treatment solutions. Technological advancements, such as the development of novel pharmaceuticals and personalized medicine approaches, offer improved treatment outcomes and reduced symptom severity, fostering market growth. Moreover, the increasing adoption of telemedicine services and home-based treatment options creates new avenues for market players to reach a wider patient population.

Market Restraints:

Despite promising growth prospects, the IBS treatment market faces challenges related to regulatory compliance, reimbursement policies, and the high cost of certain therapies. Stringent regulations governing the approval and marketing of IBS treatments impose compliance burdens on manufacturers and healthcare providers, affecting market entry barriers and operational costs. Furthermore, limited reimbursement coverage for certain IBS treatments and the economic burden on patients pose challenges for market penetration, particularly in emerging economies with constrained healthcare budgets. Addressing these regulatory and economic barriers requires collaboration between industry stakeholders and policymakers to promote access to safe and affordable IBS treatments.

Market Opportunities:

The IBS treatment market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as remote monitoring and telemedicine platforms, enhances patient access to IBS treatments and improves treatment adherence and outcomes. Furthermore, the expanding application of probiotics and microbiome-based therapies, as well as the development of novel drug delivery systems, broadens the market scope and stimulates innovation. Strategic partnerships, investment in research and development, and the introduction of user-friendly, cost-effective treatment solutions are essential to capitalize on emerging opportunities and sustain market leadership in the dynamic IBS treatment landscape.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the IBS treatment market globally?
Which treatment types and applications are driving IBS treatment adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the IBS treatment market?
Who are the key players contributing to the IBS treatment market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global IBS treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global IBS treatment market, including Takeda Pharmaceutical Company Limited, Abbott Laboratories, and Allergan Plc, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced IBS treatment solutions, including novel pharmaceuticals, probiotics, and dietary supplements, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, medical device distributors, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving IBS treatment landscape.

Key Companies Profiled:

Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Abbott Laboratories
Novartis AG
AstraZeneca PLC
Ironwood Pharmaceuticals Inc. and Allergan Plc
Bausch Health Companies Inc.
GlaxoSmithKline, Plc.
Lexicon Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.

Key Segments Covered in Irritable Bowel Syndrome Treatment Industry Research

By Product:

Fiber Supplements
Anti-Diarrheal
Anticholinergic and Antispasmodic
Antidepressant
Antibiotics
Alosetron
Lubiprostone
Linaclotide
NHE3

By Indication:

Irritable Bowel Syndrome with Constipation
Irritable Bowel Syndrome with Diarrhoea
Irritable Bowel Syndrome with alternating Constipation and Diarrhoea

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies and Stores
Hypermarkets and Supermarkets

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

Product Code: PMRREP9938

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Product Adoption Analysis
4.2. Key Regulations
4.3. PESTEL Analysis
4.4. Pipeline Assessment
4.5. Porter's Analysis
4.6. Value Chain Analysis
4.7. Promotional Strategies, By Key Manufacturers

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Global Gastrointestinal Treatment Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Increase in R&D Spending
- 5.2.2. Growing Lifestyle Disease Prevalence
- 5.2.3. Cost of Drug
- 5.2.4. Adoption Rate of Treatment
- 5.2.5. Strategic Collaborations
- 5.2.6. Changes in Regulatory Policies
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Product
- 6.1.2. By Indication
- 6.1.3. By Distribution Channel
- 6.1.4. By Country
6.2. 2024 Market Scenario

7. Global Irritable Bowel Syndrome Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Product

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Product, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
- 8.3.1. Fiber Supplements
- 8.3.2. Anti-Diarrheal
- 8.3.3. Anticholinergic and Antispasmodic
- 8.3.4. Antidepressant
- 8.3.5. Antibiotics
- 8.3.6. Alosetron
- 8.3.7. Lubiprostone
- 8.3.8. Linaclotide
- 8.3.9. NHE3
8.4. Market Attractiveness Analysis By Product

9. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2033
- 9.3.1. Irritable Bowel Syndrome with Constipation
- 9.3.2. Irritable Bowel Syndrome with Diarrhea
- 9.3.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
9.4. Market Attractiveness Analysis By Indication

10. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Drug Stores
- 10.3.4. Online Pharmacies and Stores
- 10.3.5. Hypermarkets and Supermarkets
10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region

11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. East Asia
- 11.3.5. South Asia
- 11.3.6. Oceania
- 11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region

12. North America Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 12.3.1. By Country
  - 12.3.1.1. U.S.
  - 12.3.1.2. Canada
- 12.3.2. By Product
- 12.3.3. By Indication
- 12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Product
- 12.4.3. By Indication
- 12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Players - Intensity Mapping
12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Irritable Bowel Syndrome Treatment Market Analysis
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.1.2.1. By Product
    - 12.8.1.2.2. By Indication
    - 12.8.1.2.3. By Distribution Channel
- 12.8.2. Canada Irritable Bowel Syndrome Treatment Market Analysis
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.2.2.1. By Product
    - 12.8.2.2.2. By Indication
    - 12.8.2.2.3. By Distribution Channel

13. Latin America Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. Mexico
  - 13.3.1.2. Brazil
  - 13.3.1.3. Argentina
  - 13.3.1.4. Rest of Latin America
- 13.3.2. By Product
- 13.3.3. By Indication
- 13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Product
- 13.4.3. By Indication
- 13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
- 13.8.1. Mexico Irritable Bowel Syndrome Treatment Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Product
    - 13.8.1.2.2. By Indication
    - 13.8.1.2.3. By Distribution Channel
- 13.8.2. Brazil Irritable Bowel Syndrome Treatment Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Product
    - 13.8.2.2.2. By Indication
    - 13.8.2.2.3. By Distribution Channel
- 13.8.3. Argentina Irritable Bowel Syndrome Treatment Market Analysis
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.3.2.1. By Product
    - 13.8.3.2.2. By Indication
    - 13.8.3.2.3. By Distribution Channel

14. Europe Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. Germany
  - 14.3.1.2. Italy
  - 14.3.1.3. France
  - 14.3.1.4. U.K.
  - 14.3.1.5. Spain
  - 14.3.1.6. BENELUX
  - 14.3.1.7. Russia
  - 14.3.1.8. Rest of Europe
- 14.3.2. By Product
- 14.3.3. By Indication
- 14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Product
- 14.4.3. By Indication
- 14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
- 14.8.1. Germany Irritable Bowel Syndrome Treatment Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Product
    - 14.8.1.2.2. By Indication
    - 14.8.1.2.3. By Distribution Channel
- 14.8.2. Italy Irritable Bowel Syndrome Treatment Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Product
    - 14.8.2.2.2. By Indication
    - 14.8.2.2.3. By Distribution Channel
- 14.8.3. France Irritable Bowel Syndrome Treatment Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Product
    - 14.8.3.2.2. By Indication
    - 14.8.3.2.3. By Distribution Channel
- 14.8.4. U.K. Irritable Bowel Syndrome Treatment Market Analysis
  - 14.8.4.1. Introduction
  - 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.4.2.1. By Product
    - 14.8.4.2.2. By Indication
    - 14.8.4.2.3. By Distribution Channel
- 14.8.5. Spain Irritable Bowel Syndrome Treatment Market Analysis
  - 14.8.5.1. Introduction
  - 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.5.2.1. By Product
    - 14.8.5.2.2. By Indication
    - 14.8.5.2.3. By Distribution Channel
- 14.8.6. BENELUX Irritable Bowel Syndrome Treatment Market Analysis
  - 14.8.6.1. Introduction
  - 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.6.2.1. By Product
    - 14.8.6.2.2. By Indication
    - 14.8.6.2.3. By Distribution Channel
- 14.8.7. Russia Irritable Bowel Syndrome Treatment Market Analysis
  - 14.8.7.1. Introduction
  - 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.7.2.1. By Product
    - 14.8.7.2.2. By Indication
    - 14.8.7.2.3. By Distribution Channel

15. East Asia Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. China
  - 15.3.1.2. Japan
  - 15.3.1.3. South Korea
- 15.3.2. By Product
- 15.3.3. By Indication
- 15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Product
- 15.4.3. By Indication
- 15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
- 15.8.1. China Irritable Bowel Syndrome Treatment Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Product
    - 15.8.1.2.2. By Indication
    - 15.8.1.2.3. By Distribution Channel
- 15.8.2. Japan Irritable Bowel Syndrome Treatment Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Product
    - 15.8.2.2.2. By Indication
    - 15.8.2.2.3. By Distribution Channel
- 15.8.3. South Korea Irritable Bowel Syndrome Treatment Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Product
    - 15.8.3.2.2. By Indication
    - 15.8.3.2.3. By Distribution Channel

16. South Asia Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. India
  - 16.3.1.2. Indonesia
  - 16.3.1.3. Malaysia
  - 16.3.1.4. Thailand
  - 16.3.1.5. Rest of South Asia
- 16.3.2. By Product
- 16.3.3. By Indication
- 16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Product
- 16.4.3. By Indication
- 16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
- 16.8.1. India Irritable Bowel Syndrome Treatment Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Product
    - 16.8.1.2.2. By Indication
    - 16.8.1.2.3. By Distribution Channel
- 16.8.2. Indonesia Irritable Bowel Syndrome Treatment Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Product
    - 16.8.2.2.2. By Indication
    - 16.8.2.2.3. By Distribution Channel
- 16.8.3. Malaysia Irritable Bowel Syndrome Treatment Market Analysis
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.3.2.1. By Product
    - 16.8.3.2.2. By Indication
    - 16.8.3.2.3. By Distribution Channel
- 16.8.4. Thailand Irritable Bowel Syndrome Treatment Market Analysis
  - 16.8.4.1. Introduction
  - 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.4.2.1. By Product
    - 16.8.4.2.2. By Indication
    - 16.8.4.2.3. By Distribution Channel

17. Oceania Irritable Bowel Syndrome Treatment Market 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. Australia
  - 17.3.1.2. New Zealand
- 17.3.2. By Product
- 17.3.3. By Indication
- 17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Product
- 17.4.3. By Indication
- 17.4.4. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
- 17.8.1. Australia Irritable Bowel Syndrome Treatment Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Product
    - 17.8.1.2.2. By Indication
    - 17.8.1.2.3. By Distribution Channel
- 17.8.2. New Zealand Irritable Bowel Syndrome Treatment Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Product
    - 17.8.2.2.2. By Indication
    - 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Irritable Bowel Syndrome Treatment Market Analysis 2019-2023 and Forecast 2024-2033

18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 18.3.1. By Country
  - 18.3.1.1. GCC Countries
  - 18.3.1.2. Turkey
  - 18.3.1.3. North Africa
  - 18.3.1.4. South Africa
  - 18.3.1.5. Rest of Middle East and Africa
- 18.3.2. By Product
- 18.3.3. By Indication
- 18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Product
- 18.4.3. By Indication
- 18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Key Players - Intensity Mapping
18.8. Country Level Analysis & Forecast
- 18.8.1. GCC Countries Irritable Bowel Syndrome Treatment Market Analysis
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.1.2.1. By Product
    - 18.8.1.2.2. By Indication
    - 18.8.1.2.3. By Distribution Channel
- 18.8.2. Turkey Irritable Bowel Syndrome Treatment Market Analysis
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.2.2.1. By Product
    - 18.8.2.2.2. By Indication
    - 18.8.2.2.3. By Distribution Channel
- 18.8.3. South Africa Irritable Bowel Syndrome Treatment Market Analysis
  - 18.8.3.1. Introduction
  - 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.3.2.1. By Product
    - 18.8.3.2.2. By Indication
    - 18.8.3.2.3. By Distribution Channel
- 18.8.4. North Africa Irritable Bowel Syndrome Treatment Market Analysis
  - 18.8.4.1. Introduction
  - 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.4.2.1. By Product
    - 18.8.4.2.2. By Indication
    - 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis

20. Competition Analysis

20.1. Competition Dashboard
20.2. Competition Deep Dive
- 20.2.1. Pfizer, Inc.
  - 20.2.1.1. Overview
  - 20.2.1.2. Product Portfolio
  - 20.2.1.3. Sales Footprint
  - 20.2.1.4. Key Financials
  - 20.2.1.5. SWOT Analysis
  - 20.2.1.6. Strategy Overview
    - 20.2.1.6.1. Marketing Strategy
    - 20.2.1.6.2. Product Strategy
    - 20.2.1.6.3. Channel Strategy
- 20.2.2. Takeda Pharmaceutical Company Limited
  - 20.2.2.1. Overview
  - 20.2.2.2. Product Portfolio
  - 20.2.2.3. Sales Footprint
  - 20.2.2.4. Key Financials
  - 20.2.2.5. SWOT Analysis
  - 20.2.2.6. Strategy Overview
    - 20.2.2.6.1. Marketing Strategy
    - 20.2.2.6.2. Product Strategy
    - 20.2.2.6.3. Channel Strategy
- 20.2.3. Abbott Laboratories
  - 20.2.3.1. Overview
  - 20.2.3.2. Product Portfolio
  - 20.2.3.3. Sales Footprint
  - 20.2.3.4. Key Financials
  - 20.2.3.5. SWOT Analysis
  - 20.2.3.6. Strategy Overview
    - 20.2.3.6.1. Marketing Strategy
    - 20.2.3.6.2. Product Strategy
    - 20.2.3.6.3. Channel Strategy
- 20.2.4. Novartis AG
  - 20.2.4.1. Overview
  - 20.2.4.2. Product Portfolio
  - 20.2.4.3. Sales Footprint
  - 20.2.4.4. Key Financials
  - 20.2.4.5. SWOT Analysis
  - 20.2.4.6. Strategy Overview
    - 20.2.4.6.1. Marketing Strategy
    - 20.2.4.6.2. Product Strategy
    - 20.2.4.6.3. Channel Strategy
- 20.2.5. AstraZeneca PLC
  - 20.2.5.1. Overview
  - 20.2.5.2. Product Portfolio
  - 20.2.5.3. Sales Footprint
  - 20.2.5.4. Key Financials
  - 20.2.5.5. SWOT Analysis
  - 20.2.5.6. Strategy Overview
    - 20.2.5.6.1. Marketing Strategy
    - 20.2.5.6.2. Product Strategy
    - 20.2.5.6.3. Channel Strategy
- 20.2.6. Ironwood Pharmaceuticals Inc. and Allergan Plc
  - 20.2.6.1. Overview
  - 20.2.6.2. Product Portfolio
  - 20.2.6.3. Sales Footprint
  - 20.2.6.4. Key Financials
  - 20.2.6.5. SWOT Analysis
  - 20.2.6.6. Strategy Overview
    - 20.2.6.6.1. Marketing Strategy
    - 20.2.6.6.2. Product Strategy
    - 20.2.6.6.3. Channel Strategy
- 20.2.7. Bausch Health Companies Inc.
  - 20.2.7.1. Overview
  - 20.2.7.2. Product Portfolio
  - 20.2.7.3. Sales Footprint
  - 20.2.7.4. Key Financials
  - 20.2.7.5. SWOT Analysis
  - 20.2.7.6. Strategy Overview
    - 20.2.7.6.1. Marketing Strategy
    - 20.2.7.6.2. Product Strategy
    - 20.2.7.6.3. Channel Strategy
- 20.2.8. GlaxoSmithKline, Plc.
  - 20.2.8.1. Overview
  - 20.2.8.2. Product Portfolio
  - 20.2.8.3. Sales Footprint
  - 20.2.8.4. Key Financials
  - 20.2.8.5. SWOT Analysis
  - 20.2.8.6. Strategy Overview
    - 20.2.8.6.1. Marketing Strategy
    - 20.2.8.6.2. Product Strategy
    - 20.2.8.6.3. Channel Strategy
- 20.2.9. Lexicon Pharmaceuticals, Inc.
  - 20.2.9.1. Overview
  - 20.2.9.2. Product Portfolio
  - 20.2.9.3. Sales Footprint
  - 20.2.9.4. Key Financials
  - 20.2.9.5. SWOT Analysis
  - 20.2.9.6. Strategy Overview
    - 20.2.9.6.1. Marketing Strategy
    - 20.2.9.6.2. Product Strategy
    - 20.2.9.6.3. Channel Strategy
- 20.2.10. Sucampo Pharmaceuticals, Inc.
  - 20.2.10.1. Overview
  - 20.2.10.2. Product Portfolio
  - 20.2.10.3. Sales Footprint
  - 20.2.10.4. Key Financials
  - 20.2.10.5. SWOT Analysis
  - 20.2.10.6. Strategy Overview
    - 20.2.10.6.1. Marketing Strategy
    - 20.2.10.6.2. Product Strategy
    - 20.2.10.6.3. Channel Strategy